How Does Ketamine Work for Depression? What Is Known and What Is Theory

The honest short answer is that nobody knows exactly. What is known is how ketamine acts on a particular receptor in the brain. What researchers are still working out is how that action turns into changes in mood that, in studies, have lasted for days after a single dose, long after most of the drug has left the body.

It helps to keep those two layers apart. Established pharmacology describes what the drug does at the receptor in anyone who receives it. Hypotheses about depression try to explain why some people feel better afterward and others do not. Be cautious with any source that blurs the two, including clinic websites.

Glutamate is the chief signal nerve cells use to excite one another, and the NMDA receptor is one of the receptors it acts on. The FDA prescribing information describes ketamine as a non-selective, non-competitive antagonist of the NMDA receptor, meaning it blocks the receptor rather than switching it on, and attributes its anesthetic effects primarily to that blockade in the brain and spinal cord.

The same document lists other effects that are established rather than theoretical. Ketamine raises blood pressure, heart rate and cardiac output; it produces a dissociative state, a sense of detachment from your body or surroundings; and as it wears off it can cause dream-like experiences or confusion. These effects are part of why ketamine treatment is given where a clinician can monitor you.

One leading explanation, summarized in a 2018 review in Molecular Psychiatry by Zanos and Gould, begins with NMDA receptors on inhibitory nerve cells. Blocking those receptors is thought to take the brakes off neighboring neurons, which fire more and release a burst of glutamate.

That burst is thought to activate a different glutamate receptor, the AMPA receptor, and to switch on growth signals inside cells involving a protein called BDNF and a pathway called mTOR. In animal research, this chain of events is linked to lasting strengthening of excitatory synapses, the connections between nerve cells, which may help explain why mood effects can outlast the drug itself.

The surge theory is not the only candidate. The same review describes evidence that blocking NMDA receptors located outside the synapse may matter, and that some of ketamine's breakdown products, the hydroxynorketamine metabolites, may act through routes that do not depend on NMDA blockade at all. The authors conclude that the proposed mechanisms are not mutually exclusive and that ketamine is unlikely to produce its full antidepressant effect through NMDA receptor inhibition alone.

For patients, the practical meaning is modest: scientists broadly agree on where ketamine acts first, and they disagree about what happens next. An explanation presented as settled fact is ahead of the evidence.

Early clinical trials focused on people whose depression had not improved with standard treatment. A 2006 crossover trial by NIMH researchers, randomized and placebo-controlled, gave 18 adults with treatment-resistant depression a single intravenous dose; their improvement began within about two hours and stayed significant for a week.

Later trials, including a two-site study that used an active comparison drug and a 2023 trial of repeated injections under the skin, also found benefit for some participants and none for others. Those studies measure groups, not individuals, and they say little about results over months or years.

Because the mechanism is debated and long-term data are limited, careful practice leans on what is known: screening before treatment, a dose worked out for the individual, monitoring during every session, and reassessment after a series of sessions. Here at Clear Ketamine Therapy, each dose goes in as a small injection under the skin, at our Tampa clinic, while a clinician watches you throughout. The supply comes from a licensed outsourcing facility that compounds it, and compounded ketamine is not FDA-approved.

You do not need to understand receptor biology to be evaluated. Your consultation focuses on your history, your current treatment and your goals, and on whether ketamine therapy may be reasonable for you at all.